Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Efficacy of educational intervention to improve awareness of the importance of iodine, use of iodized salt, and dietary iodine intake in northeastern Italian schoolchildren.

Watutantrige-Fernando S, Barollo S, Bertazza L, Cavedon E, Censi S, Manso J, Vianello F; Food Hygiene, Nutrition Services SIAN, Mian C.

Nutrition. 2018 Sep;53:134-139. doi: 10.1016/j.nut.2018.02.010. Epub 2018 Mar 23.

PMID:
29778950
2.

EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer.

Bertazza L, Sensi F, Cavedon E, Watutantrige-Fernando S, Censi S, Manso J, Vianello F, Casal Ide E, Iacobone M, Pezzani R, Mian C, Barollo S.

Endocrinology. 2018 Jun 1;159(6):2348-2360. doi: 10.1210/en.2018-00124.

PMID:
29688429
3.

Crude extract of Origanum vulgare L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines.

Rubin B, Manso J, Monticelli H, Bertazza L, Redaelli M, Sensi F, Zorzan M, Scaroni C, Mian C, Iacobone M, Armanini D, Bertolini C, Barollo S, Boscaro M, Pezzani R.

Nat Prod Res. 2018 Jan 15:1-4. doi: 10.1080/14786419.2018.1425846. [Epub ahead of print]

PMID:
29334260
4.

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Clin Oncol. 2018 Feb 10;36(5):438-445. doi: 10.1200/JCO.2017.74.5497. Epub 2017 Dec 14.

5.

The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes.

Watutantrige-Fernando S, Vianello F, Barollo S, Bertazza L, Galuppini F, Cavedon E, Censi S, Benna C, Ide EC, Parisi A, Nacamulli D, Iacobone M, Pennelli G, Mian C.

Thyroid. 2018 Jan;28(1):96-103. doi: 10.1089/thy.2017.0248. Epub 2018 Jan 2.

PMID:
29179638
6.

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.

Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Natl Cancer Inst. 2018 Apr 1;110(4):362-370. doi: 10.1093/jnci/djx227.

PMID:
29165667
7.

Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.

Torresan F, Cavedon E, Mian C, Iacobone M.

World J Surg. 2018 Feb;42(2):367-375. doi: 10.1007/s00268-017-4321-z.

PMID:
29134313
8.

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit.

Censi S, Cavedon E, Bertazza L, Galuppini F, Watutantrige-Fernando S, De Lazzari P, Nacamulli D, Pennelli G, Fassina A, Iacobone M, Casal Ide E, Vianello F, Barollo S, Mian C.

Front Endocrinol (Lausanne). 2017 Oct 16;8:273. doi: 10.3389/fendo.2017.00273. eCollection 2017.

9.

Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.

Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone P, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Spiazzi G, Mian C, Persani L, Barbaro D, Nicolucci A, Filetti S.

Thyroid. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299. Epub 2017 Nov 10.

PMID:
29020892
10.

MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome.

Galuppini F, Bertazza L, Barollo S, Cavedon E, Rugge M, Guzzardo V, Sacchi D, Watutantrige-Fernando S, Vianello F, Mian C, Pennelli G.

Virchows Arch. 2017 Nov;471(5):651-658. doi: 10.1007/s00428-017-2227-7. Epub 2017 Aug 31.

PMID:
28861609
11.

Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.

Cavedon E, Barollo S, Bertazza L, Pennelli G, Galuppini F, Watutantrige-Fernando S, Censi S, Iacobone M, Benna C, Vianello F, Zovato S, Nacamulli D, Mian C.

Int J Endocrinol. 2017;2017:4915736. doi: 10.1155/2017/4915736. Epub 2017 Jun 6.

12.

The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations.

Castinetti F, Maia AL, Peczkowska M, Barontini M, Hasse-Lazar K, Links TP, Toledo RA, Dvorakova S, Mian C, Bugalho MJ, Zovato S, Alevizaki M, Kvachenyuk A, Bausch B, Loli P, Bergmann SR, Patocs A, Pfeifer M, Costa JB, von Dobschuetz E, Letizia C, Valk G, Barczynski M, Czetwertynska M, Plukker JTM, Sartorato P, Zelinka T, Vlcek P, Yaremchuk S, Weryha G, Canu L, Wohllk N, Sebag F, Walz MK, Eng C, Neumann HPH.

Endocr Relat Cancer. 2017 Aug;24(8):L63-L67. doi: 10.1530/ERC-17-0189. Epub 2017 Jun 25. No abstract available.

PMID:
28649091
13.

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3241-3250. doi: 10.1210/jc.2017-00277.

PMID:
28582521
14.

Retinal Photoreceptor Functions Are Compromised in Patients With Resistance to Thyroid Hormone Syndrome (RTHβ).

Campi I, Cammarata G, Bianchi Marzoli S, Beck-Peccoz P, Santarsiero D, Dazzi D, Bottari de Castello A, Taroni EG, Viola F, Mian C, Watutantrige-Fernando S, Pelusi C, Muzza M, Maffini MA, Persani L.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2620-2627. doi: 10.1210/jc.2016-3671.

PMID:
28379567
15.

Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer.

Tuccilli C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, D'Armiento E, Antonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S, Mian C, Arcieri S, Mascagni D, Pironi D, Bononi M, Vergine M, Monti M, Filippini A, Ulisse S.

Int J Oncol. 2017 Mar 8. doi: 10.3892/ijo.2017.3907. [Epub ahead of print]

PMID:
28350047
16.

Deregulated expression of VHL mRNA variants in papillary thyroid cancer.

Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, Catania A, D'Armiento E, Antonelli A, Fallahi P, Watutantrige-Fernando S, Tartaglia F, Barollo S, Mian C, Bononi M, Arceri S, Mascagni D, Vergine M, Pironi D, Monti M, Filippini A, Ulisse S.

Mol Cell Endocrinol. 2017 Mar 5;443:121-127. doi: 10.1016/j.mce.2017.01.019. Epub 2017 Jan 12.

17.

Calcitonin measurement and immunoassay interference: a case report and literature review.

Censi S, Cavedon E, Fernando SW, Barollo S, Bertazza L, Zambonin L, Zaninotto M, Faggian D, Plebani M, Mian C.

Clin Chem Lab Med. 2016 Dec 1;54(12):1861-1870. doi: 10.1515/cclm-2015-1161. Review.

PMID:
27166721
18.

Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.

Barollo S, Bertazza L, Watutantrige-Fernando S, Censi S, Cavedon E, Galuppini F, Pennelli G, Fassina A, Citton M, Rubin B, Pezzani R, Benna C, Opocher G, Iacobone M, Mian C.

PLoS One. 2016 May 25;11(5):e0156044. doi: 10.1371/journal.pone.0156044. eCollection 2016.

19.

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.

Pezzani R, Rubin B, Bertazza L, Redaelli M, Barollo S, Monticelli H, Baldini E, Mian C, Mucignat C, Scaroni C, Mantero F, Ulisse S, Iacobone M, Boscaro M.

Invest New Drugs. 2016 Oct;34(5):531-40. doi: 10.1007/s10637-016-0358-3. Epub 2016 May 14.

PMID:
27177645
20.

BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience.

Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C.

Clin Chem Lab Med. 2016 Sep 1;54(9):1531-9. doi: 10.1515/cclm-2015-0218.

PMID:
26863344
21.

Association of primary aldosteronism with chronic thyroiditis.

Sabbadin C, Mian C, Nacamulli D, Donà G, Presotto F, Betterle C, Boscaro M, Bordin L, Armanini D.

Endocrine. 2017 Jan;55(1):303-306. doi: 10.1007/s12020-016-0880-2. Epub 2016 Feb 9. No abstract available.

PMID:
26860513
22.

Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells.

Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Fallahi P, Mian C, Barollo S, Catania A, Morrone S, Tartaglia F, Mascagni D, Coccaro C, Pepe M, Filippini A, D'Armiento M, Ulisse S.

J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):793-803.

PMID:
26753639
23.

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors.

Rubin B, Monticelli H, Redaelli M, Mucignat C, Barollo S, Bertazza L, Mian C, Betterle C, Iacobone M, Fassina A, Boscaro M, Pezzani R, Mantero F.

Cancer Invest. 2015;33(10):526-31. doi: 10.3109/07357907.2015.1080832. Epub 2015 Nov 4.

PMID:
26536286
24.

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M.

J Clin Endocrinol Metab. 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3.

25.

PAPILLARY THYROID CANCER IS CHARACTERIZED BY ALTERED EXPRESSION OF GENES INVOLVED IN THE SUMOYLATION PROCESS.

Tuccilli C, Baldini E, Sorrenti S, Di Gioia C, Bosco D, Ascoli V, Mian C, Barollo S, Rendina R, Coccaro C, Pepe M, Catania A, Bononi M, Tartaglia F, De Antoni E, D'Armiento M, Ulisse S.

J Biol Regul Homeost Agents. 2015 Jul-Sep;29(3):655-62.

PMID:
26403403
26.

A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.

Occhi G, Barollo S, Regazzo D, Bertazza L, Galuppini F, Guzzardo V, Jaffrain-Rea ML, Vianello F, Ciato D, Ceccato F, Watutantrige-Fernando S, Bisognin A, Bortoluzzi S, Pennelli G, Boscaro M, Scaroni C, Mian C.

Oncotarget. 2015 Oct 13;6(31):32104-14. doi: 10.18632/oncotarget.5194.

27.

Urinary cytology in bladder cancer: why is it still relevant?

Comploj E, Trenti E, Palermo S, Pycha A, Mian C.

Urologia. 2015 Oct-Dec;82(4):203-5. doi: 10.5301/uro.5000129. Epub 2015 Jul 15. Review.

PMID:
26219472
28.

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.

Bertazza L, Barollo S, Radu CM, Cavedon E, Simioni P, Faggian D, Plebani M, Pelizzo MR, Rubin B, Boscaro M, Pezzani R, Mian C.

J Cell Mol Med. 2015 Sep;19(9):2244-52. doi: 10.1111/jcmm.12612. Epub 2015 Jun 17.

29.

Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.

Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, De Vito C, Catania A, Tartaglia F, Mocini R, Coccaro C, Alessandrini S, Barollo S, Mian C, Antonelli A, De Antoni E, D'Armiento M, Ulisse S.

PLoS One. 2015 Mar 25;10(3):e0121514. doi: 10.1371/journal.pone.0121514. eCollection 2015.

30.

Iodine status from childhood to adulthood in females living in North-East Italy: Iodine deficiency is still an issue.

Watutantrige Fernando S, Cavedon E, Nacamulli D, Pozza D, Ermolao A, Zaccaria M, Girelli ME, Bertazza L, Barollo S, Mian C.

Eur J Nutr. 2016 Feb;55(1):335-40. doi: 10.1007/s00394-015-0853-x. Epub 2015 Feb 8.

PMID:
25663610
31.

Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review.

Sabbadin C, Donà G, Bordin L, Iacobone M, Camozzi V, Mian C, Armanini D.

BMC Endocr Disord. 2015 Jan 28;15:4. doi: 10.1186/1472-6823-15-4. Review.

32.

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V.

J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.

33.

The PDCD4/miR-21 pathway in medullary thyroid carcinoma.

Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M, Guzzardo V, Pelizzo MR, Rugge M, Mian C.

Hum Pathol. 2015 Jan;46(1):50-7. doi: 10.1016/j.humpath.2014.09.006. Epub 2014 Oct 2.

PMID:
25316501
34.

AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.

Mian C, Ceccato F, Barollo S, Watutantrige-Fernando S, Albiger N, Regazzo D, de Lazzari P, Pennelli G, Rotondi S, Nacamulli D, Pelizzo MR, Jaffrain-Rea ML, Grimaldi F, Occhi G, Scaroni C.

PLoS One. 2014 Jul 14;9(7):e101560. doi: 10.1371/journal.pone.0101560. eCollection 2014.

35.

Response to editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.

Lodde M, Mian C, Mayr R, Comploj E, Trenti E, Melotti R, Campodonico F, Maffezzini M, Fritsche HM, Pycha A.

Int J Urol. 2014 Oct;21(10):974. doi: 10.1111/iju.12531. Epub 2014 Jun 19. No abstract available.

36.

Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.

Lodde M, Mian C, Mayr R, Comploj E, Trenti E, Melotti R, Campodonico F, Maffezzini M, Fritsche HM, Pycha A.

Int J Urol. 2014 Oct;21(10):968-72. doi: 10.1111/iju.12509. Epub 2014 Jun 19.

37.

Long-term follow-up of intermediate-risk non-muscle invasive bladder cancer sub-classified by multi-coloured FISH.

Mian C, Comploj E, Resnyak E, Trenti E, Palermo S, Lodde M, Pycha A, Ambrosini-Spaltro A, Dechet CB, Pycha A.

Anticancer Res. 2014 Jun;34(6):3067-71.

PMID:
24922674
38.

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR, Cavedon E, Fugazzola L, Scarpa A.

Virchows Arch. 2014 Jul;465(1):73-8. doi: 10.1007/s00428-014-1589-3. Epub 2014 May 15.

PMID:
24828033
39.

The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.

Barollo S, Bertazza L, Baldini E, Ulisse S, Cavedon E, Boscaro M, Pezzani R, Mian C.

Invest New Drugs. 2014 Aug;32(4):626-35. doi: 10.1007/s10637-014-0108-3. Epub 2014 May 13.

PMID:
24821574
40.

Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study.

Castinetti F, Qi XP, Walz MK, Maia AL, Sansó G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA, Mian C, Bugalho MJ, Wohllk N, Kollyukh O, Canu L, Loli P, Bergmann SR, Biarnes Costa J, Makay O, Patocs A, Pfeifer M, Shah NS, Cuny T, Brauckhoff M, Bausch B, von Dobschuetz E, Letizia C, Barczynski M, Alevizaki MK, Czetwertynska M, Ugurlu MU, Valk G, Plukker JT, Sartorato P, Siqueira DR, Barontini M, Szperl M, Jarzab B, Verbeek HH, Zelinka T, Vlcek P, Toledo SP, Coutinho FL, Mannelli M, Recasens M, Demarquet L, Petramala L, Yaremchuk S, Zabolotnyi D, Schiavi F, Opocher G, Racz K, Januszewicz A, Weryha G, Henry JF, Brue T, Conte-Devolx B, Eng C, Neumann HP.

Lancet Oncol. 2014 May;15(6):648-55. doi: 10.1016/S1470-2045(14)70154-8. Epub 2014 Apr 15.

PMID:
24745698
41.

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.

Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.

Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008. Epub 2014 Mar 18.

PMID:
24721322
42.

Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety.

Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, De Leo S, Sarais C, Cacciatore C, Manfredi GI, Verga U, Iacobone M, De Pasquale L, Pelizzo MR, Vicentini L, Persani L, Fugazzola L.

J Clin Endocrinol Metab. 2014 May;99(5):1656-64. doi: 10.1210/jc.2013-4088. Epub 2014 Feb 19.

PMID:
24552221
43.

Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.

Russo E, Salzano M, De Falco V, Mian C, Barollo S, Secondo A, Bifulco M, Vitale M.

Clin Cancer Res. 2014 Mar 15;20(6):1513-20. doi: 10.1158/1078-0432.CCR-13-1683. Epub 2014 Jan 21.

44.

Selenium and autoimmune thyroiditis.

Nacamulli D, Petricca D, Mian C.

J Endocrinol Invest. 2013 Nov;36(10 Suppl):8-14.

PMID:
24419054
45.

Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.

Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C.

Thyroid. 2014 May;24(5):809-19. doi: 10.1089/thy.2013.0403. Epub 2014 Jan 23.

PMID:
24295088
46.

Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer.

Comploj E, Dechet CB, Mian M, Trenti E, Palermo S, Lodde M, Mian C, Ambrosini-Spaltro A, Horninger W, Pycha A.

World J Urol. 2014 Oct;32(5):1219-23. doi: 10.1007/s00345-013-1197-x. Epub 2013 Oct 29.

PMID:
24166290
47.

The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells.

Pezzani R, Rubin B, Redaelli M, Radu C, Barollo S, Cicala MV, Salvà M, Mian C, Mucignat-Caretta C, Simioni P, Iacobone M, Mantero F.

Endocr J. 2014;61(1):41-53. Epub 2013 Oct 24.

48.

Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.

Fong D, Moser P, Kasal A, Seeber A, Gastl G, Martowicz A, Wurm M, Mian C, Obrist P, Mazzoleni G, Spizzo G.

Histopathology. 2014 Apr;64(5):683-92. doi: 10.1111/his.12307. Epub 2013 Dec 2.

PMID:
24117877
49.

Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.

Pelizzo MR, Torresan F, Boschin IM, Nacamulli D, Pennelli G, Barollo S, Rubello D, Mian C.

Am J Clin Oncol. 2015 Oct;38(5):508-13. doi: 10.1097/COC.0b013e3182a78fec.

PMID:
24064755
50.

Cytology as an alternative to frozen section at the time of nephron-sparing surgery to evaluate surgical margin status.

Palermo SM, Dechet C, Trenti E, Mian C, Lodde M, Comploj E, Mazzoleni G, Hanspeter E, Ambrosini Spaltro A, Mayr R, Pycha A.

Urology. 2013 Nov;82(5):1071-5. doi: 10.1016/j.urology.2013.06.050. Epub 2013 Sep 14.

PMID:
24044918

Supplemental Content

Support Center